<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739501</url>
  </required_header>
  <id_info>
    <org_study_id>0987654321</org_study_id>
    <nct_id>NCT04739501</nct_id>
  </id_info>
  <brief_title>Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors</brief_title>
  <official_title>Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiological response after trans arterial chemoembolization (TACE) is classified according&#xD;
      to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) to: complete response (CR)&#xD;
      (disappearance of arterial enhancement), partial response (PR) ( at least a 30% decrease in&#xD;
      the sum of diameters of viable enhancement), progressive disease (PD) (an increase of at&#xD;
      least 20% in the sum of the diameters of viable enhancement, or appearance of new lesions),&#xD;
      and stable disease (any cases that do not qualify for either partial response or progressive&#xD;
      disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      POST-TACE response of treatment for cases of hepatocellular cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>35 Months</target_duration>
  <primary_outcome>
    <measure>Post_TACE hepatic cell failure</measure>
    <time_frame>1 year</time_frame>
    <description>Frequency of liver cell failure in form of jaundice , coagulopathy and encephalopathy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>TACE in HCC group 1</arm_group_label>
    <description>the patient did undergo tace</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Trans-arterial chemoembolization in patients with hepatocellular carcinoma</description>
    <arm_group_label>TACE in HCC group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HCC with TACE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinical history and examination with special stress on symptoms and signs of chronic liver&#xD;
        disease with or without evidence of hepatic decompensation e.g. the presence of ascites and&#xD;
        with or without evidence of complications e.g. jaundice spider naevi, bleeding varices,&#xD;
        ascites, and lower limb edema.&#xD;
&#xD;
        Laboratory findings in the form of raised bilirubin and liver enzymes, impaired coagulation&#xD;
        profile, and/or low serum albumin.&#xD;
&#xD;
        Abdominal ultrasonography revealing liver cirrhosis (coarse echopattern, attenuated hepatic&#xD;
        veins, irregular outlines, hypertrophy of caudate lobe and/or shrunken liver, presence of&#xD;
        focal hepatic) and presence of splenomegaly, ascites, or portal vein thrombosis (PVT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient who had surgical resection or liver transplantation Patients refuse to&#xD;
        participate Hepatic focal lesion other than HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amany M Ahmed</last_name>
    <phone>01146457697</phone>
    <email>mahranamany18@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amany M Mahran, Residents</last_name>
      <phone>01146457697</phone>
      <email>Mahranamany18@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amany Mahran Mohammed Ahmed</investigator_full_name>
    <investigator_title>resident of tropical medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

